外科理论与实践

外科理论与实践 >

2025 , Vol. 30 >Issue 05: 450 - 455

DOI: https://doi.org/10.16139/j.1007-9610.2025.05.12

综述

肠道微生态在肝细胞癌发生发展中的研究进展及其对临床诊疗的潜在应用

  • 张天齐 ,
  • 刘洋 ,
  • 魏云巍
展开
  • 1.宁波大学 医学部, 浙江 宁波 315211
    2.宁波市第二医院肝胆胰外科， 浙江 宁波 315010
    3.宁波市肠道微生态与人类重大疾病重点实验室，浙江 宁波 315010
刘洋，E-mail: lyang712@icloud.com；
魏云巍，E-mail: hydwyw11@hotmail.com

收稿日期: 2025-05-05

  网络出版日期: 2025-12-09

基金资助

国家自然科学基金(82300631);宁波市医疗卫生高端团队重大攻坚项目(2022010101)

收起

Advances in the study of intestinal microecology in the development of hepatocellular carcinoma and its implications for clinical diagnosis and treatment

  • ZHANG Tianqi ,
  • LIU Yang ,
  • WEI Yunwei
Expand
  • 1. Health Science Center, Ningbo University, Zhejiang Ningbo 315211, China
    2. Department of Hepatobiliary and Pancreatic Surgery, Ningbo No.2 Hospital, Zhejiang Ningbo 315010, China
    3. Key Laboratory of Intestinal Microecology and Major Human Disease in Ningbo, Zhejiang Ningbo 315010, China

Received date: 2025-05-05

  Online published: 2025-12-09

Fold

摘要

肠道微生态与肝细胞癌（hepatocellular carcinoma，HCC）发生与发展关系密切。肠道菌群及其代谢产物可通过“肠-肝轴”调控肿瘤免疫微环境，促进癌症进展。因此，肠道微生物组逐渐展现出作为HCC早期诊断和免疫治疗疗效预测生物标志物的潜力。靶向肠道微生态干预（如益生菌、粪便菌群移植、饮食调控等）可增强免疫检查点抑制剂（ICIs）疗效，正在成为具有前景的联合治疗策略。未来，HCC治疗将依托多组学整合、人工智能辅助诊疗与合成生物学手段，推动肠道菌群精准干预策略从基础研究向临床转化。本文综述了肠道微生态在HCC中的最新研究进展，探讨其在HCC精准诊疗中的潜在价值及发展方向，为相关干预策略的临床应用提供理论依据。

关键词： 肠道微生态; 肝细胞癌; 肠道微生物

本文引用格式

张天齐 , 刘洋 , 魏云巍 . 肠道微生态在肝细胞癌发生发展中的研究进展及其对临床诊疗的潜在应用[J]. 外科理论与实践, 2025 , 30(05) : 450 -455 . DOI: 10.16139/j.1007-9610.2025.05.12

Abstract

The intestinal microecology is closely related to the occurrence and development of hepatocellular carcinoma (HCC). The intestinal microbiota and its metabolites can regulate the tumor immune microenvironment through the "gut-liver axis", promoting cancer progression. Therefore, the intestinal microbiome is gradually demonstrating the potential as a biomarker for early diagnosis of HCC and prediction of the efficacy of immunotherapy. Targeted intervention on the intestinal microecology (such as probiotics, fecal microbiota transplantation, dietary regulation, etc.) may enhance the efficacy of immune checkpoint inhibitors (ICIs) and is becoming a promising combination therapy strategy. In the future, HCC treatment will rely on multi-omics integration, artificial intelligence-assisted diagnosis, and synthetic biology tools to promote the translation of precise gut flora intervention strategies from basic research to the clinic. This article summarized the latest research progress of intestinal microecology in HCC, explored its potential value and development direction for precision diagnosis and treatment of HCC, and provided a theoretical basis for the clinical application of related intervention strategies.

Key words： Intestinal microecology; Hepatocellular carcinoma(HCC); Intestinal microbiome

参考文献

[1] YANG J, YANG Y, ISHII M, et al. Does the gut microbiota modulate host physiology through polymicrobial biofilms?[J]. Microbes Environ, 2020, 35(3):ME20037.
[2] MCKENNA P, HOFFMANN C, MINKAH N, et al. The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis[J]. PLoS Pathog, 2008, 4(2):e20.
[3] THOMAS A M, FIDELLE M, ROUTY B, et al. Gut oncomicrobiome signatures (GOMS) as next-generation biomarkers for cancer immunotherapy[J]. Nat Rev Clin Oncol, 2023, 20(9):583-603.
[4] 许芳琪, 李博文, 刘洋, 等. 具核梭杆菌通过E-cadherin/β-catenin信号上调结直肠癌ABCG2表达诱导奥沙利铂耐药[J]. 中华肿瘤杂志, 2025, 47(4):329-339.
  XU F Q, LI B W, LIU Y, et al. Fusobacterium nucleatum upregulates ABCG2 by activating the E-cadherin/β-catenin signaling pathway to promote oxaliplatin resistance in colorectal cancer[J]. Chin J Oncol, 2025, 47(4):329-339.
[5] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[6] BEHARY J, AMORIM N, JIANG X T, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma[J]. Nat Commun, 2021, 12(1):187.
[7] TRIPATHI A, DEBELIUS J, BRENNER D A, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7):397-411.
[8] WANG X, FANG Y, LIANG W, et al. Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice[J]. Nat Microbiol, 2025, 10(1):169-184.
[9] PONTAROLLO G, KOLLAR B, MANN A, et al. Commensal bacteria weaken the intestinal barrier by suppressing epithelial neuropilin-1 and Hedgehog signaling[J]. Nat Metab, 2023, 5(7):1174-1187.
[10] MANFREDO VIEIRA S, HILTENSPERGER M, KUMAR V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359(6380):1156-1161.
[11] XING L, ZHANG Y, LI S, et al. A dual coverage monitoring of the bile acids profile in the liver-gut axis throughout the whole inflammation-cancer transformation progressive: reveal hepatocellular carcinoma pathogenesis[J]. Int J Mol Sci, 2023, 24(5):4258.
[12] LIANG Z, LI S, WANG Z, et al. Unraveling the role of the Wnt pathway in hepatocellular carcinoma: from molecular mechanisms to therapeutic implications[J]. J Clin Transl Hepatol, 2025, 13(4):315-326.
[13] LIN W, LI S, MENG Y, et al. UDCA inhibits hypoxic hepatocellular carcinoma cell-induced angiogenesis through suppressing HIF-1α/VEGF/IL-8 intercellular signaling[J]. Front Pharmacol, 2021,12:755394.
[14] WILLEMSEN L E, KOETSIER M A, VAN DEVENTER S J, et al. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts[J]. Gut, 2003, 52(10):1442-1447.
[15] LOUIS P, FLINT H J. Formation of propionate and buty-rate by the human colonic microbiota[J]. Environ Microbiol, 2017, 19(1):29-41.
[16] WANG W, DERNST A, MARTIN B, et al. Butyrate and propionate are microbial danger signals that activate the NLRP3 inflammasome in human macrophages upon TLR stimulation[J]. Cell Rep, 2024, 43(9):114736.
[17] HAN J, ZHANG S, XU Y, et al. Beneficial effect of antibiotics and microbial metabolites on expanded Vδ2Vγ9 T cells in hepatocellular carcinoma immunotherapy[J]. Front Immunol, 2020,11:1380.
[18] CHEN W, WEN L, BAO Y, et al. Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2[J]. Proc Natl Acad Sci USA, 2022, 119(52):e2203894119.
[19] SEYMOUR B J, TRENT B, ALLEN B E, et al. Microbiota-dependent indole production stimulates the deve-lopment of collagen-induced arthritis in mice[J]. J Clin Invest, 2023, 134(4):e167671.
[20] SHI Z, GAN G, GAO X, et al. Kynurenine catabolic enzyme KMO regulates HCC growth[J]. Clin Transl Med, 2022, 12(2):e697.
[21] TANG H, WU L. MAMPs: a devil tamed becomes an angel[J]. Cell Host Microbe, 2023, 31(9):1422-1425.
[22] FITZGERALD K A, KAGAN J C. Toll-like receptors and the control of immunity[J]. Cell, 2020, 180(6):1044-1066.
[23] SCHWABE R F, GRETEN T F. Gut microbiome in HCC - mechanisms, diagnosis and therapy[J]. J Hepatol, 2020, 72(2):230-238.
[24] YAMAGISHI R, KAMACHI F, NAKAMURA M, et al. Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma[J]. Sci Immunol, 2022, 7(72):eabl7209.
[25] BHATT A P, SARTOR R B. 'Bugs on drugs': implications for gut health[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5):287-288.
[26] BAI W, XIAO J. Third international symposium on phytochemicals in medicine and food[J]. Crit Rev Food Sci Nutr, 2019, 59(sup1):S1-S3.
[27] KIM S Y, AN J, LIM Y S, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma[J]. JAMA Oncol, 2017, 3(4):456-463.
[28] XU F, ZHANG L, HE W, et al. The diagnostic value of serum PIVKA-Ⅱ alone or in combination with AFP in Chinese hepatocellular carcinoma patients[J]. Dis Mar-kers, 2021,2021:8868370.
[29] ZHANG H, WU J, LIU Y, et al. Identification reprodu-cible microbiota biomarkers for the diagnosis of cirrhosis and hepatocellular carcinoma[J]. AMB Express, 2023, 13(1):35.
[30] ZHENG C, LU F, CHEN B, et al. Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma[J]. Cancer Sci, 2023, 114(12):4717-4731.
[31] FINN R S, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
[32] YAU T, ZAGONEL V, SANTORO A, et al. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the checkmate 040 trial[J]. J Clin Oncol, 2023, 41(9):1747-1757.
[33] ZHOU C B, ZHOU Y L, FANG J Y. Gut microbiota in cancer immune response and immunotherapy[J]. Trends Cancer, 2021, 7(7):647-660.
[34] SIMPSON R C, SHANAHAN E R, SCOLYER R A, et al. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2023, 20(10):697-715.
[35] ROUTY B, LE CHATELIER E, DEROSA L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371):91-97.
[36] HU J, WANG C, YE L, et al. Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice[J]. J Biosci, 2015, 40(2):269-279.
[37] PONZIANI F R, DE LUCA A, PICCA A, et al. Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma[J]. Hepatol Commun, 2022, 6(6):1492-1501.
[38] GONG X, SHEN L, XIE J, et al. Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: a systematic review and meta-analysis[J]. Helicobacter, 2023, 28(6):e13011.
[39] COUTZAC C, JOUNIAUX J M, PACI A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer[J]. Nat Commun, 2020, 11(1):2168.
[40] MAGER L F, BURKHARD R, PETT N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J]. Science, 2020, 369(6510):1481-1489.
[41] MIRJI G, WORTH A, BHAT S A, et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer[J]. Sci Immunol, 2022, 7(75):eabn0704.
[42] ZHU X, HU M, HUANG X, et al. Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses[J]. Cell Metab, 2025, 37(4):806-823.e6.
[43] ZHANG Z, HUANG W, HU D, et al. E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression[J]. Gut, 2025, 74(7):1137-1149.
[44] LIU X, YANG W, PETRICK J L, et al. Higher intake of whole grains and dietary fiber are associated with lower risk of liver cancer and chronic liver disease mortality[J]. Nat Commun, 2021, 12(1):6388.
[45] KOMEIL I A, EL-REFAIE W M, GOWAYED M A, et al. Oral genistein-loaded phytosomes with enhanced hepatic uptake, residence and improved therapeutic efficacy against hepatocellular carcinoma[J]. Int J Pharm, 2021,601:120564.
[46] PINATO D J, LI X, MISHRA-KALYANI P, et al. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma[J]. JHEP Rep, 2023, 5(6):100747.
[47] FESSAS P, NAEEM M, PINTER M, et al. Early anti-biotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma[J]. Liver Cancer, 2021, 10(6):583-592.
[48] SHI K, ZHANG Q, ZHANG Y, et al. Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis[J]. Front Cell Infect Microbiol, 2022,12:1104399.
[49] ARAI N, MIURA K, AIZAWA K, et al. Probiotics suppress nonalcoholic steatohepatitis and carcinogenesis progression in hepatocyte-specific PTEN knockout mice[J]. Sci Rep, 2022, 12(1):16206.
[50] CAMMAROTA G, IANIRO G, TILG H, et al. European consensus conference on faecal microbiota transplantation in clinical practice[J]. Gut, 2017, 66(4):569-580.
[51] LOPETUSO L R, DELEU S, GODNY L, et al. The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease[J]. Gut, 2023, 72(9):1642-1650.
[52] HUANG M, JI Q, HUANG H, et al. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification[J]. Gut Microbes, 2025, 17(1):2486519.
[53] CHANG Z, GUO X, LI X, et al. Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization[J]. Cell, 2025, 188(7):1842-1857.e20.
Options
文章导航

/

〈 〉